Nguyen C, Reimers M, Perera C, Abida W, Chou J, Feng F
Clin Cancer Res. 2024; 30(15):3200-3210.
PMID: 38787530
PMC: 11293970.
DOI: 10.1158/1078-0432.CCR-24-0400.
Zhang H, Zhou Y, Feng Y, Hou W, Chen Y, Xing Z
Clin Transl Med. 2024; 14(5):e1678.
PMID: 38736108
PMC: 11089090.
DOI: 10.1002/ctm2.1678.
Lu K, Li Z, Zhang Q, Yin Q, Zhang Y, Ni W
Sci Rep. 2024; 14(1):6574.
PMID: 38503865
PMC: 10951204.
DOI: 10.1038/s41598-024-56831-7.
Hawlina S, Zorec R, Chowdhury H
Life (Basel). 2023; 13(7).
PMID: 37511873
PMC: 10382052.
DOI: 10.3390/life13071498.
Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock A, Bergom H
Clin Cancer Res. 2023; 29(19):3948-3957.
PMID: 37477913
PMC: 10543965.
DOI: 10.1158/1078-0432.CCR-23-1393.
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.
Conteduca V, Brighi N, Schepisi G, De Giorgi U
Br J Cancer. 2023; 129(7):1050-1060.
PMID: 37443349
PMC: 10539309.
DOI: 10.1038/s41416-023-02354-3.
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.
Filippone M, Gaglio D, Bonfanti R, Tucci F, Ceccacci E, Pennisi R
Nat Commun. 2022; 13(1):2642.
PMID: 35550508
PMC: 9098894.
DOI: 10.1038/s41467-022-30375-8.
Analysis of CDK12 alterations in a pan-cancer database.
Pan E, Cabal A, Javier-Desloges J, Patel D, Panian J, Lee S
Cancer Med. 2021; 11(3):753-763.
PMID: 34898046
PMC: 8817093.
DOI: 10.1002/cam4.4483.
Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S
Int J Mol Sci. 2021; 22(18).
PMID: 34575947
PMC: 8471942.
DOI: 10.3390/ijms22189783.
Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur H, Vidotto T, Mendes A, Salles D, Isaacs W, Antonarakis E
Cancer Immunol Immunother. 2021; 71(4):943-951.
PMID: 34533610
PMC: 9254167.
DOI: 10.1007/s00262-021-03050-y.
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
Melo C, Vidotto T, Chaves L, Lautert-Dutra W, Dos Reis R, Squire J
Int J Mol Sci. 2021; 22(17).
PMID: 34502458
PMC: 8431051.
DOI: 10.3390/ijms22179550.
CDK12: cellular functions and therapeutic potential of versatile player in cancer.
Pilarova K, Herudek J, Blazek D
NAR Cancer. 2021; 2(1):zcaa003.
PMID: 34316683
PMC: 8210036.
DOI: 10.1093/narcan/zcaa003.
Targeting the spectrum of immune checkpoints in prostate cancer.
Sena L, Denmeade S, Antonarakis E
Expert Rev Clin Pharmacol. 2021; 14(10):1253-1266.
PMID: 34263692
PMC: 8484035.
DOI: 10.1080/17512433.2021.1949287.
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X
Am J Cancer Res. 2021; 11(5):1913-1935.
PMID: 34094661
PMC: 8167670.
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?.
Ruiz de Porras V, Pardo J, Notario L, Etxaniz O, Font A
Int J Mol Sci. 2021; 22(9).
PMID: 33946818
PMC: 8124759.
DOI: 10.3390/ijms22094712.
Changing the History of Prostate Cancer with New Targeted Therapies.
Polo S, Moreno Munoz D, Rosero Rodriguez A, Silva Ruiz J, Rosero Rodriguez D, Counago F
Biomedicines. 2021; 9(4).
PMID: 33917592
PMC: 8067446.
DOI: 10.3390/biomedicines9040392.
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Maughan B, Antonarakis E
Expert Opin Pharmacother. 2021; 22(12):1625-1632.
PMID: 33827356
PMC: 8419006.
DOI: 10.1080/14656566.2021.1912015.
CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.
Qi J, Yang Z, Lin T, Ma L, Wang Y, Zhang Y
J Exp Clin Cancer Res. 2021; 40(1):2.
PMID: 33390186
PMC: 7780414.
DOI: 10.1186/s13046-020-01814-5.
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R, Castro E, Aragon I, Cendon Y, Cattrini C, Lopez-Casas P
Br J Cancer. 2020; 124(3):552-563.
PMID: 33106584
PMC: 7851123.
DOI: 10.1038/s41416-020-01114-x.
Is There a Role for Immunotherapy in Prostate Cancer?.
Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F
Cells. 2020; 9(9).
PMID: 32911806
PMC: 7564598.
DOI: 10.3390/cells9092051.
